This page in English

Diego Cortese

Anknuten

Besöksadress : Karolinska Universitetssjukhuset, Solna, Cmm (L8:02) 171 76 Stockholm
Leveransadress : Karolinska Universitetssjukhuset, Solna, Cmm (L8:02) 171 76 Stockholm

Publikationer

UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
Bhoi S, Baliakas P, Cortese D, Mattsson M, Engvall M, Smedby Ke, et al
Haematologica 2016;101(2):e63-5

Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations
Ljungström V, Cortese D, Young E, Pandzic T, Mansouri L, Plevova K, et al
Blood 2016;127(8):1007-16

Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia
Mansouri L, Sutton La, Ljungström V, Bondza S, Arngården L, Bhoi S, et al
The Journal of experimental medicine 2015;212(6):833-43

Recurrent mutations refine prognosis in chronic lymphocytic leukemia
Baliakas P, Hadzidimitriou A, Sutton La, Rossi D, Minga E, Villamor N, et al
Leukemia 2015;29(2):329-36

Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting
Sutton La, Ljungström V, Mansouri L, Young E, Cortese D, Navrkalova V, et al
Haematologica 2015;100(3):370-6

On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort
Cortese D, Sutton La, Cahill N, Smedby Ke, Geisler C, Gunnarsson R, et al
Leukemia 2014;28(3):710-3

Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2
Strefford Jc, Sutton La, Baliakas P, Agathangelidis A, Malcikova J, Plevova K, et al
LEUKEMIA 2013;27(11):2196-9

Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?
Rosenquist R, Cortese D, Bhoi S, Mansouri L, Gunnarsson R
Leukemia & lymphoma 2013;54(11):2351-64